Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.74 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600191 | 0.89 | KRAS (0.71) | KRAS | |
| SCHEMBL30669296 | 0.87 | KRAS (0.73) | KRAS | |
| SCHEMBL26197763 | 0.86 | KRAS (0.85) | KRAS | |
| SCHEMBL31323318 | 0.86 | KRAS (0.77) | KRAS | |
| SCHEMBL25258381 | 0.85 | KRAS (1.00) | KRAS | |
| SCHEMBL29679993 | 0.85 | KRAS (0.74) | KRAS | |
| SCHEMBL23053640 | 0.85 | KRAS (1.00) | KRAS | |
| SCHEMBL24535700 | 0.85 | KRAS (0.74) | KRAS | |
| SCHEMBL25419226 | 0.84 | KRAS (0.66) | KRASRAF1 | |
| SCHEMBL24536207 | 0.84 | KRAS (0.80) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339976-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885RAF1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.